Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, pg 2835, 2023)

被引：0

作者：

Kirkwood, John M. ^{[1
]}

Del Vecchio, Michele ^{[2
]}

Weber, Jeffrey ^{[3
]}

Hoeller, Christoph ^{[4
]}

Grob, Jean-Jacques ^{[5
]}

Mohr, Peter ^{[6
]}

Loquai, Carmen ^{[7
]}

Dutriaux, Caroline ^{[8
]}

Chiarion-Sileni, Vanna ^{[9
]}

Mackiewicz, Jacek ^{[10
]}

Rutkowski, Piotr ^{[11
,12
,13
]}

Arenberger, Petr

Quereux, Gaelle ^{[14
]}

Meniawy, Tarek M. ^{[15
,16
]}

Ascierto, Paolo A. ^{[17
]}

Menzies, Alexander M. ^{[18
,19
]}

Durani, Piyush ^{[20
]}

Lobo, Maurice ^{[20
]}

Campigotto, Federico ^{[20
]}

Gastman, Brian ^{[21
]}

Long, Georgina V. ^{[18
,19
]}

机构：

[1] UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA

[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[3] NYU Langone Med Ctr, New York, NY USA

[4] Med Univ Wien, Vienna, Austria

[5] Hop La Timone, Marseille, France

[6] Elbe Klinikum Buxtehude, Buxtehude, Germany

[7] Univ Med Ctr Mainz, Mainz, Germany

[8] Hop St Andre, Bordeaux, France

[9] IOV IRCCS, Ist Oncol Veneto, Padua, Italy

[10] Poznan Univ Med Sci, Inst Oncol, Poznan, Poland

[11] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[12] Charles Univ Prague, Fac Med 3, Prague, Czech Republic

[13] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic

[14] Nantes Univ Hosp, Nantes, France

[15] Univ Western Australia, Perth, WA, Australia

[16] Charles Gairdner Hosp, Perth, WA, Australia

[17] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[18] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[19] Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[20] Bristol Myers Squibb, Princeton, NJ USA

[21] Cleveland Clin, Cleveland, OH USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 03期

关键词：

D O I：

10.1038/s41591-023-02775-w

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：906 / 906

页数：1

共 35 条

[21] Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial (vol 402, pg 798, 2023)
Becker, J. C.
Ugurel, S.
Leiter, U.
LANCET, 2023, 402 (10411): : 1422 - 1422
[22] EORTC 18991:: long term adjuvant pegylated interferon-α2b (PEG-IFN) vs observation in resected stage III melanoma:: final results of a randomized phase 3 trial
Eggermont, A. M. M.
Suciu, S.
Santinami, M.
Kruit, W.
Testori, A.
Marsden, J.
Punt, C. J. A.
Hauschild, A.
Gore, M.
Keilholz, U.
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2007, 299 (5-6) : 298 - 299
[23] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767
[24] Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group (vol 27, pg 2916, 2009)
Bottomley
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4630 - 4630
[25] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Eggermont, Alexander M. M.
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Giacomo, Anna Maria Di
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Lorigan, Paul C.
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
LANCET ONCOLOGY, 2021, 22 (05): : 643 - 654
[26] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Bottomley, Andrew
Coens, Corneel
Mierzynska, Justyna
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Puig, Susana
Ascierto, Paolo A.
Larkin, James
Lorigan, Paul C.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Di Giacomo, Anna Maria
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
Eggermont, Alexander M. M.
LANCET ONCOLOGY, 2021, 22 (05): : 655 - 664
[27] Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial (vol 402, pg 859, 2023)
Lafayette, R.
Kristensen, J.
Stone, A.
LANCET, 2023, 402 (10405): : 850 - 850
[28] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 41, pg 4852, 2023)
Goto, Koichi
Goto, Yasushi
Kubo, Toshio
Ninomiya, Kiichiro
Kim, Sang-We
Planchard, David
Ahn, Myung-Ju
Smit, Egbert F.
de Langen, Adrianus Johannes
Perol, Maurice
Pons-Tostivint, Elvire
Novello, Silvia
Hayashi, Hidetoshi
Shimizu, Junichi
Kim, Dong-Wan
Kuo, Chih-Hsi
Yang, James Chih-Hsin
Pereira, Kaline
Cheng, Fu-Chih
Taguchi, Ayumi
Cheng, Yingkai
Feng, Wenqin
Tsuchihashi, Zenta
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04) : 485 - 485
[29] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Buehrer, Emanuel
Kicinski, Michal
Mandala, Mario
Pe, Madeline
Long, Georgina, V
Atkinson, Victoria
Blank, Christian U.
Haydon, Andrew
Dalle, Stephane
Khattak, Adnan
Carlino, Matteo S.
Meshcheryakov, Andrey
Sandhu, Shahneen
Puig, Susana
Schadendorf, Dirk
Jamal, Rahima
Rutkowski, Piotr
van den Eertwegh, Alfonsus J. M.
Coens, Corneel
Grebennik, Dmitri
Krepler, Clemens
Robert, Caroline
Eggermont, Alexander
LANCET ONCOLOGY, 2024, 25 (09): : 1202 - 1212
[30] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
Motzer, R. J.
Powles, T.
Burotto, M.
LANCET ONCOLOGY, 2022, 23 (07): : E319 - E319

← 1 2 3 4 →